8-K: Personalis Reports Strong First Quarter 2025 Financial Results Driven by Pharma Growth

Personalis, Inc. announced a 6% increase in revenue for Q1 2025, driven by a 39% surge in pharma tests and services revenue and a 52% increase in clinical test volume.

Summary

• Personalis, Inc. reported its financial results for the first quarter of 2025, ended March 31, 2025.
• Total revenue for Q1 2025 was $20.6 million, a 6% increase compared to $19.5 million in Q1 2024.
• Pharma tests and services revenue increased by 39% year-over-year, reaching $13.6 million.
• Population sequencing and enterprise sales decreased by 29% to $6.7 million due to an expected decline in volume from Natera.
• Clinical test volume increased by 52% sequentially, with 2,184 tests delivered in Q1 2025.
• Gross margin improved to 35.0% from 28.1% in the prior year, driven by a favorable revenue mix.
• Net loss was $15.8 million, or $0.18 per share, compared to a net loss of $13.0 million, or $0.26 per share, in Q1 2024.
• The company's cash, cash equivalents, and short-term investments totaled $185.7 million as of March 31, 2025.
• Personalis raised $17.8 million in net proceeds from selling common stock under its At-The-Market (ATM) program.
• For Q2 2025, Personalis expects total revenue to be in the range of $19.5 to $20.5 million.
• For the full year 2025, Personalis maintains its revenue guidance of $80 to $90 million.
• The company expects a net loss of approximately $83 million for the full year 2025.
• Cash usage is projected to be approximately $75 million for the full year 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company shows revenue growth and improvements in gross margin, but also an increased net loss. The strong growth in pharma tests and services and the clinical validation of NeXT Personal are positive indicators, but the reliance on a few key customers and the need for further reimbursement approvals present risks.

Positives

• Revenue increased by 6% year-over-year in Q1 2025.
• Pharma tests and services revenue saw a significant increase of 39%.
• Clinical test volume increased by 52% sequentially.
• Gross margin improved to 35.0% from 28.1% in the prior year.
• The company has a strong cash position of $185.7 million.
• NeXT Personal showed compelling clinical evidence in colorectal cancer.
• Gross margin guidance increased from 21-23% to 22-24%.
• Net loss guidance decreased from $85 million to $83 million.
• Cash usage guidance decreased from $75-80 million to $75 million.

Negatives

• Net loss increased to $15.8 million from $13.0 million in the prior year.
• Population sequencing and enterprise sales decreased by 29% due to the expected decline in volume from Natera.
• Cash usage of $20.5 million from operations and capital equipment additions in the first quarter of 2025.
• Gross margin in the range of 22% to 24% is lower than the 32% gross margin for the full year of 2024 as the company invests to drive clinical usage ahead of reimbursement.

Risks

• The company's success depends on the timing and pace of new orders from customers, including ModernaTX, Inc., Merck Sharp & Dohme LLC, and VA MVP.
• The timing of tissue, blood, and other specimen sample receipts from customers can materially impact revenue.
• The company's ability to demonstrate the attributes, advantages, or clinical validity of the NeXT platform is crucial.
• Reimbursement challenges in building the clinical laboratory business could impact the company's ability to cover costs.
• Competition and macroeconomic factors could negatively impact the business.
• Partnering and/or collaboration arrangements may not be successful or may terminate.
• The company has a limited number of suppliers and customer concentration.

Future Outlook

Personalis expects total company revenue to be in the range of $80 to $90 million for the full year of 2025, with revenue from pharma tests and services in the range of $62 to $64 million. The company anticipates a net loss of approximately $83 million and cash usage of approximately $75 million for the full year.

Management Comments

• 'This year is off to a great start, with strong first quarter testing growth, and we remain confident that our Win-in-MRD strategy is working,' said Chris Hall, Chief Executive Officer and President.
• He added that the company crossed the milestone of 2,000 tests delivered and submitted breast cancer data for Medicare coverage with expectations of a favorable outcome by the end of the year.
• He also noted compelling clinical evidence in colorectal cancer suggesting their ultrasensitive approach can provide a leap in performance and that they are pleased with how rapidly NeXT Personal is growing in the marketplace.

Industry Context

Personalis is operating in the precision oncology and genomics space, competing with companies offering similar molecular testing and MRD detection services. The growth in pharma tests and services indicates a strong demand for personalized medicine in drug development and clinical trials. The company's focus on MRD detection and recurrence monitoring aligns with the industry trend towards early cancer detection and personalized treatment strategies.

Comparison to Industry Standards

• Personalis's 39% year-over-year growth in pharma tests and services is a strong indicator of its competitive position in the precision oncology market.
• Companies like Guardant Health and Exact Sciences also focus on liquid biopsy and MRD detection, but Personalis's NeXT Personal platform appears to offer unique advantages in terms of sensitivity and early detection, as highlighted by the colorectal cancer study.
• The company's efforts to secure Medicare reimbursement for its breast cancer test are crucial for expanding its clinical reach and competing with established diagnostic players.
• Personalis's gross margin of 35% is competitive with other companies in the diagnostics industry, but the company's investment in clinical usage ahead of reimbursement is expected to lower gross margins in the near term.

Related Party Transactions

• Related party revenue of $0.5 million for the three months ended March 31, 2025.
• Related party sales and marketing expenses of $0.6 million for the three months ended March 31, 2025.
• Related party accounts receivable of $0.5 million as of March 31, 2025.
• Related party liabilities of $2.8 million as of March 31, 2025.
• Related party liabilities of $1.2 million as of March 31, 2025.

Stakeholder Impact

• Shareholders: The financial results and future outlook will impact shareholder value.
• Employees: The company's growth and strategic initiatives will affect employment opportunities and job security.
• Customers: The performance and adoption of Personalis's products will impact patient outcomes and treatment decisions.
• Suppliers: The company's financial performance will influence its ability to meet its obligations to suppliers.
• Creditors: The company's cash position and financial stability will affect its creditworthiness.

Next Steps

• Continue to drive adoption of NeXT Personal in the marketplace.
• Secure Medicare reimbursement coverage for the breast cancer test.
• Expand clinical studies to further validate the performance of NeXT Personal.
• Invest in commercial capabilities to drive growth.
• Focus on the Win-in-MRD strategy.

Key Dates

Keywords

Personalis, genomics, oncology, financial results, revenue, pharma tests, clinical tests, NeXT Personal, MRD, ctDNA, Medicare, reimbursement